Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction A Cohort Study

被引:39
作者
Booth, John N., III [1 ]
Colantonio, Lisandro D. [1 ]
Chen, Ligong [1 ]
Rosenson, Robert S. [4 ]
Monda, Keri L. [5 ]
Safford, Monika M. [7 ]
Kilgore, Meredith L. [2 ]
Brown, Todd M. [3 ]
Taylor, Benjamin [5 ]
Dent, Ricardo [6 ]
Muntner, Paul [1 ]
Levitan, Emily B. [1 ]
机构
[1] Univ Alabama Birmingham, Dept Epidemiol, 1700 Univ Blvd,LHL 452, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Hlth Care Org & Policy, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA
[4] Mt Sinai Icahn Sch Med, Dept Med, New York, NY USA
[5] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA
[6] Amgen Inc, Global Dev, Thousand Oaks, CA 91320 USA
[7] Weill Cornell Med, Dept Med, New York, NY USA
来源
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES | 2017年 / 10卷 / 10期
关键词
Medicare; myocardial infarction; secondary prevention; statins; CORONARY-HEART-DISEASE; SECONDARY PREVENTION; THERAPY; CARE; ATORVASTATIN; ADHERENCE; DYNAMICS; CLAIMS; RATES;
D O I
10.1161/CIRCOUTCOMES.117.003626
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Although the benefits of statins accrue over time, treatment discontinuation is common. Examining the patterns of statin discontinuation, reinitiation, and persistence after reinitiation among Medicare beneficiaries after hospital discharge for a myocardial infarction may help increase statin use in high-risk patients. Methods and Results-Medicare beneficiaries with a statin fill claim within 30 days after hospital discharge for myocardial infarction in 2007 to 2012 (n = 158 795) were followed for 182 days post-discharge to identify discontinuation, defined as 60 continuous days without statins available. Reinitiation, defined by a statin fill, was identified in the 365 days post-discontinuation. High persistence was defined as proportion of days covered >= 80% with >= 1 day of statin supply 182 days after reinitiation. Follow-up ended on December 31, 2014. In the 182 days after myocardial infarction hospital discharge, 15.4% of beneficiaries discontinued statins. Of this group, 53.7% reinitiated statins. On reinitiation, 27.1% changed statin type, 6.9% up-titrated intensity, 14.4% down-titrated intensity, and 66.0% had the same statin and intensity. In the 182 days after reinitiation, 45.8% had high persistence. Moderate-and high-versus low-intensity statins were associated with a lower risk for statin discontinuation (moderate intensity: relative risk [RR], 0.93; 95% confidence interval [CI], 0.89-0.96; high-intensity: RR, 0.95; 95% CI, 0.91-0.99). High persistence was less common after reinitiating high-versus low-intensity statins (RR, 0.80; 95% CI, 0.75-0.86), but no association was present for those reinitiating a moderate-versus low-intensity statin (RR, 0.95; 95% CI, 0.90-1.01). Down-titrating versus reinitiating the same statin intensity (RR, 1.10; 95% CI, 1.05-1.16) and reinitiating a different versus the same statin (RR, 1.10; 95% CI, 1.06-1.14) were associated with high persistence after treatment reinitiation. Conclusions-Although many people who discontinue a statin reinitiate treatment, statin persistence after reinitiation was low. Reinitiating therapy with moderate-intensity statins, down-titration, and using a different statin may promote persistence.
引用
收藏
页数:31
相关论文
共 28 条
[1]   Long-term persistence in use of statin therapy in elderly patients [J].
Benner, JS ;
Glynn, RJ ;
Mogun, H ;
Neumann, PJ ;
Weinstein, MC ;
Avorn, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (04) :455-461
[2]   Physician follow-up and provider continuity are associated with long-term medication adherence - A study of the dynamics of statin use [J].
Brookhart, M. Alan ;
Patrick, Amanda R. ;
Schneeweiss, Sebastian ;
Avorn, Jerry ;
Dormuth, Colin ;
Shrank, William ;
van Wijk, Boris L. G. ;
Cadarette, Suzanne M. ;
Canning, Claire F. ;
Solomon, Daniel H. .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (08) :847-852
[3]   Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes [J].
Cannon, Christopher P. ;
Blazing, Michael A. ;
Giugliano, Robert P. ;
McCagg, Amy ;
White, Jennifer A. ;
Theroux, Pierre ;
Darius, Harald ;
Lewis, Basil S. ;
Ophuis, Ton Oude ;
Jukema, J. Wouter ;
De Ferrari, Gaetano M. ;
Ruzyllo, Witold ;
De Lucca, Paul ;
Im, KyungAh ;
Bohula, Erin A. ;
Reist, Craig ;
Wiviott, Stephen D. ;
Tershakovec, Andrew M. ;
Musliner, Thomas A. ;
Braunwald, Eugene ;
Califf, Robert M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) :2387-2397
[4]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[5]   Compliance with a statin treatment in a usual-care setting: Retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia [J].
Caspard, H ;
Chan, AK ;
Walker, AM .
CLINICAL THERAPEUTICS, 2005, 27 (10) :1639-1646
[6]   Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data [J].
Colantonio, Lisandro D. ;
Kent, Shia T. ;
Huang, Lei ;
Chen, Ligong ;
Monda, Keri L. ;
Serban, Maria-Corina ;
Manthripragada, Angelika ;
Kilgore, Meredith L. ;
Rosenson, Robert S. ;
Muntner, Paul .
CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (05) :525-533
[7]   Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use [J].
Colantonio, Lisandro D. ;
Kent, Shia T. ;
Kilgore, Meredith L. ;
Delzell, Elizabeth ;
Curtis, Jeffrey R. ;
Howard, George ;
Safford, Monika M. ;
Muntner, Paul .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (07) :827-835
[8]   Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review [J].
De Vera, Mary A. ;
Bhole, Vidula ;
Burns, Lindsay C. ;
Lacaille, Diane .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (04) :684-698
[9]   Suboptimal statin adherence and discontinuation in primary and secondary prevention populations - Should we target patients with the most to gain? [J].
Ellis, JJ ;
Erickson, SR ;
Stevenson, JG ;
Bernstein, SJ ;
Stiles, RA ;
Fendrick, AM .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2004, 19 (06) :638-645
[10]   A systematic review of statin-induced muscle problems in clinical trials [J].
Ganga, Harsha V. ;
Slim, Hanna B. ;
Thompson, Paul D. .
AMERICAN HEART JOURNAL, 2014, 168 (01) :6-15